Catalyst Pharmaceuticals Faces Pivotal Earnings Release

Investors in Catalyst Pharmaceuticals are bracing for a significant market-moving event this week as the biopharma company prepares to release its third-quarter 2025 financial results. The upcoming earnings announcement, scheduled for Wednesday, is anticipated to set the near-term trajectory for the company’s stock performance.

The financial community will be closely examining Catalyst’s earnings report, due after market close on November 5. Current forecasts present a contrasting picture of the company’s performance. Revenue is projected to increase by 6 percent to $136.43 million, while earnings per share are expected to decline by 10.5 percent to $0.51. According to consensus estimates from three market analysts, the average EPS prediction stands at just $0.48, with individual forecasts ranging Read more...